Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin plus metformin versus glipizide plus metformin in adults with type 2 diabetes mellitus inadequately controlled on metformin
2007-003998-55Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin plus metformin with Glipizide plus metformin (2 arms). Primary endpoints: Change from baseline in HbA1c at 52 weeks and Non-inferiority of saxagliptin plus metformin versus glipizide plus metformin for HbA1c change at 52 weeks. Started Oct 2007; status: completed.
02
Drugs
saxagliptinglipizidemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-003998-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003998-55.